CAR-T cells enhanced with navigation system to penetrate lymph nodes more efficiently
· Medical Xpressby Max Delbrück Center for Molecular Medicine
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Lead Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
Chimeric antigen receptor T-cell therapy, or CAR-T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to recognize and attack tumor cells. It offers many patients long-lasting remission and even a cure. Yet the approach still fails in many lymphomas—cancers that affect the lymphatic system—especially when cancer cells are located in lymph nodes.
Researchers at the Max Delbrück Center, led by Dr. Uta Höpken, group leader of the Microenvironmental Regulation in Autoimmunity and Cancer lab at the Max Delbrück Center, and Dr. Maria Zschummel, a former doctoral student in her lab, have found a way to help CAR-T cells reach their targets. By engineering the cells to express the receptor CCR7, the team improved both their ability to migrate into lymph nodes and to kill lymphoma cells. The research was published in Cancer Immunology Research.
"Many lymphomas grow primarily in lymph nodes," explains Zschummel, now a postdoctoral researcher at Massachusetts General Hospital in Boston.
"If therapeutic immune cells cannot reach these sites efficiently, even powerful therapies may fail. By restoring the receptor CCR7, we essentially gave the cells a better navigation system to find the tumor."
Better homing and a quick death
"Under normal conditions, immune cells use CCR7 to guide them into lymph nodes," explains Höpken, whose lab has been studying the receptor for many years. However, the manufacturing process used to produce CAR-T cells reduces expression of this receptor, which limits the cells' ability to migrate into lymph node tissue.
To overcome this problem, the researchers tweaked the genetic engineering of CAR-T cells so that they permanently express CCR7. They then tested the modified cells in a series of experiments using human immune cells, lymphoma cell lines and mouse models of lymphoma.
They found that their CAR-T-CCR7 cells regained the ability to migrate into lymph nodes and accumulated more efficiently. In mouse models, these cells also eliminated lymphoma cells more effectively than conventional CAR-T cells.
"This was a surprise," says Zschummel.
"We expected improved migration, but CCR7 also boosted the cells' killing efficiency."
More effective immunotherapy
The work has important implications for cancer therapy. Boosting the ability of CAR-T cells to zero in on lymphoma cells has the potential to make the therapy more effective. It may also reduce the incidence of cancer relapse.
The strategy could also be applied to other cancers that spread to lymph nodes, adds Höpken, senior author of the paper.
"We show that improving the 'navigation system' of immune cells can make them generally more effective fighters against cancer."
Before the approach can reach patients, further studies will need to evaluate safety and long-term effects, she adds.
"Nevertheless, the work highlights how insights from basic immunology can help refine next-generation cell therapies."
More information
Maria Zschummel et al, Engineered CCR7 Overexpression Enhances Nodal CAR T-cell Homing and Cytotoxicity toward B-cell Lymphoma, Cancer Immunology Research (2026). DOI: 10.1158/2326-6066.cir-25-1381
Key medical concepts
Clinical categories
OncologyAllergy and immunology Provided by Max Delbrück Center for Molecular Medicine Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: CAR-T cells enhanced with navigation system to penetrate lymph nodes more efficiently (2026, June 7) retrieved 8 June 2026 from https://medicalxpress.com/news/2026-06-car-cells-penetrate-lymph-nodes.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.